Cardiol Therapeutics (CRDL) Competitors $1.34 +0.23 (+20.72%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.34 +0.00 (+0.37%) As of 08/14/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDL vs. GOSS, CGEM, SVRA, SNDL, MBX, ATYR, CMPS, KMDA, UPXI, and RGNXShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Gossamer Bio (GOSS), Cullinan Therapeutics (CGEM), Savara (SVRA), SNDL (SNDL), MBX Biosciences (MBX), aTyr Pharma (ATYR), COMPASS Pathways (CMPS), Kamada (KMDA), Upexi (UPXI), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. Its Competitors Gossamer Bio Cullinan Therapeutics Savara SNDL MBX Biosciences aTyr Pharma COMPASS Pathways Kamada Upexi REGENXBIO Gossamer Bio (NASDAQ:GOSS) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation. Do institutionals and insiders have more ownership in GOSS or CRDL? 81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 6.7% of Gossamer Bio shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate GOSS or CRDL? Gossamer Bio presently has a consensus target price of $8.50, indicating a potential upside of 333.67%. Cardiol Therapeutics has a consensus target price of $8.00, indicating a potential upside of 497.01%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Gossamer Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is GOSS or CRDL more profitable? Cardiol Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -344.81%. Cardiol Therapeutics' return on equity of -209.63% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer Bio-344.81% -1,774.72% -46.73% Cardiol Therapeutics N/A -209.63%-141.09% Which has better valuation & earnings, GOSS or CRDL? Cardiol Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$114.70M3.89-$56.53M-$0.62-3.16Cardiol TherapeuticsN/AN/A-$26.77M-$0.34-3.94 Which has more risk & volatility, GOSS or CRDL? Gossamer Bio has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Does the media refer more to GOSS or CRDL? In the previous week, Gossamer Bio had 13 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 21 mentions for Gossamer Bio and 8 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.89 beat Gossamer Bio's score of 0.63 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Cardiol Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGossamer Bio and Cardiol Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.77M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-3.9422.0530.2925.74Price / SalesN/A742.42463.41115.83Price / CashN/A184.4138.2159.48Price / Book6.094.838.826.15Net Income-$26.77M$31.61M$3.25B$265.06M7 Day Performance35.92%4.55%3.70%2.60%1 Month Performance3.88%5.69%5.84%2.83%1 Year Performance-34.31%12.71%29.92%25.58% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol Therapeutics2.5331 of 5 stars$1.34+20.7%$8.00+497.0%-32.7%$91.77MN/A-3.9420News CoverageEarnings ReportGap UpHigh Trading VolumeGOSSGossamer Bio3.9012 of 5 stars$2.17+8.5%$8.25+280.2%+137.0%$454.60M$114.70M-9.43180High Trading VolumeCGEMCullinan Therapeutics1.6343 of 5 stars$7.94+3.5%$30.00+277.8%-53.3%$452.64MN/A-2.7330SVRASavara1.9774 of 5 stars$2.57-0.8%$5.60+117.9%-29.3%$447.65MN/A-5.3520News CoverageEarnings ReportSNDLSNDL2.2303 of 5 stars$1.64-0.6%$4.00+143.9%-2.3%$433.58M$671.81M-6.072,516Options VolumeGap DownMBXMBX Biosciences2.5583 of 5 stars$12.54-8.8%$37.57+199.6%N/A$419.14MN/A0.0036News CoverageATYRaTyr Pharma2.184 of 5 stars$5.02+6.8%$20.20+302.4%+169.7%$418.32M$230K-6.2053Earnings ReportShort Interest ↑Analyst RevisionCMPSCOMPASS Pathways2.5957 of 5 stars$4.60+6.0%$16.29+254.0%-38.3%$416.39MN/A-2.50120KMDAKamada4.5869 of 5 stars$7.19-0.4%$13.00+80.8%+37.0%$415.19M$160.95M24.79360News CoverageEarnings ReportShort Interest ↓UPXIUpexi2.9932 of 5 stars$5.02+9.1%$15.50+208.8%+94.2%$411.06M$26M0.00130Analyst UpgradeShort Interest ↑Gap DownRGNXREGENXBIO4.241 of 5 stars$8.33+1.7%$31.63+279.7%-24.1%$410.81M$83.33M-2.68370Gap Down Related Companies and Tools Related Companies GOSS Alternatives CGEM Alternatives SVRA Alternatives SNDL Alternatives MBX Alternatives ATYR Alternatives CMPS Alternatives KMDA Alternatives UPXI Alternatives RGNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDL) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access